TAM June/July 2020 CME Posttest
Continuing Medical Education Posttest
The following Topics in Antiviral Medicine™ issue offers continuing medical education (CME) credit:
June/July 2020, Volume 28, Issue 2
- CME Credit Available: 2.25 AMA PRA Category 1 Credits™
- Release Date: July 31, 2020
- Expiration Date: July 31, 2021
To complete the activity, read each article and successfully complete the posttest and evaluation form, which will help us evaluate this activity and plan future activities. Your responses will not affect your CME credit.
On completion of this activity, the learner will be able to:Describe the research strategies and challenges to achieve HIV eradication
- Describe the important new data presented at the 2020 Conference on Retroviruses and Opportunistic Infections and the potential clinical implications for patients in the areas of epidemiology of HIV and HIV prevention efforts
- Describe the important new data presented at the 2020 Conference on Retroviruses and Opportunistic Infections and the potential clinical implications for patients in the area of tuberculosis coinfection, cryptococcosis, and talaromycosis
- Identify the comprehensive, culturally sensitive, and developmentally sensitive care practices for youth and adolescents infected or at-risk for infection with HIV and sexually transmitted infection
Assessment of Needs
The IAS–USA offers this state-of-the-art activity as part of a nationwide CME effort for physicians in the evolving challenges of managing HIV and HCV infections.
This enduring material is designed for physicians who are actively involved in the medical care of people with HIV and other viral infections.
This activity is also relevant for other practitioners, including nurse practitioners, nurses, physician assistants, pharmacists, and others.
The International Antiviral Society–USA (IAS–USA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The IAS–USA designates this enduring material for a maximum of 2.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This CME activity is offered from July 31, 2020, to July 31, 2021. Participants who successfully complete the activity posttest and submit the evaluation and registration forms are eligible to receive CME credit. Physicians (MDs, DOs, and international equivalents) may receive CME credit for completing this activity. Other health care practitioners will receive a certificate of participation.
Disclosure of Financial Interests
It is the policy of the IAS–USA to ensure balance, independence, objectivity, and scientific rigor in all its educational activities. All faculty members (planners, speakers, presenters, etc) participating in IAS–USA-sponsored activities are required to disclose to the program audience any financial relationships with commercial interests within the past 12 months that could be perceived to influence, or give the appearance of potentially influencing, the written or oral presentation. The Accreditation Council for Continuing Medical Education (ACCME) defines a financial interest as an interest in any amount and defines a commercial interest as “any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests—unless the provider of clinical service is owned, or controlled by, an ACCME-defined commercial interest.” The information is intended to make the IAS–USA audience aware of speaker and contributor interests and commitments with commercial interests, enabling the audience members to form their own judgments about such associations.
Each author or contributor is required to complete this financial disclosure declaration. In accordance with IAS–USA policy, the IAS–USA will identify and resolve ahead of time any possible conflicts of interest that may influence CME activities with regard to exposition or conclusion. Financial relationship information about authors is included here and at the end of each article; information on the TAM Editorial Board may be found here.
Faculty disclosure information
The nonstaff members of the Topics in Antiviral Medicine™ Editorial Board participate in a volunteer capacity. They are not compensated for their role in overseeing the program.
This activity is part of the IAS–USA national educational effort that is funded, in part, by charitable contributions from commercial companies. Per IAS–USA policy, any effort that uses commercial grants must receive grants from several companies with competing products. Funds are pooled and distributed to activities at the sole discretion of the IAS–USA. Grantors have no input into any activity, including its content, development, or selection of topics or speakers. Generous support for this activity has been received from the following contributors:
Independent educational grants for the 2020 Improving the Management of HIV Disease® CME program:
Gilead Sciences, Inc
Merck & Co, Inc
Additional support provided by Janssen Therapeutics.
Drug and Product Disclaimer
This activity may contain information about the investigational uses of drugs or products that are not approved by the US Food and Drug Administration. Please consult full prescribing information before using any medication or product mentioned in this activity.
The views and opinions expressed herein are those of faculty and do not necessarily represent the opinions or recommendations of IAS–USA.
If you have any questions about this activity, please contact the IAS–USA:
Mail: 131 Steuart St, Ste 500, San Francisco, CA 94105
Phone: (415) 544-9400
By clicking the link below, I acknowledge that I have read these instructions and understand them.
You must log in to take the activity.